Business
Bausch Health Announces Third Quarter 2025 Results
Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Orga...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health Announces Third Quarter 2025 ResultsThird Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 millionConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 million acquired In-Process Research & Development (\"IPR&D\") charge, up 8% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2025 RESULTSDelivered tenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP)1 growth, with 7% Reported and 5% Organic (non-GAAP)1 Revenue growth, and 7% Adjusted EBITDA (non-GAAP)1 growth, including an $81 million charge for acquired IPR&DRaising full-year 2025 Revenue, Adjusted EBITDA (non-GAAP)1, and Adjusted Cash Flow from Operations (non-GAAP)1 guidanceCompleted acquisition of DURECT Corporation, expanding Bausch Health's hepatology portfolio with addition of lead asset, Larsucosterol, a novel epigenetic modulator with FDA Breakthrough Therapy Designation for treatment of alcohol-associated hepatitis (\"AH\") LAVAL, QC / ACCESS Newswire / October 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\" or the \"Company\" or \"we\" or \"our\") today announced its third quarter 2025 financial results and other key updates from the quarter.\"The third quarter marks our tenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, highlighting our team's consistent execution and operational excellence. The completion of our acquisition of DURECT Corporation in the quarter further strengthens our growth platform in R&D, complementing our existing hepatology pipeline and broadening the reach of our diverse portfolio across therapeutic areas and geographies. As we approach the close of 2025, we remain focused on executing against our strategic priorities, driving strong year-end performance, and unlocking value for shareholders.\" said Thomas J. Appio, Chief Executive Officer, Bausch Health.Third Quarter 2025 Revenue PerformanceTotal consolidated reported revenues were $2.68 billion for the third quarter of 2025, compared with $2.51 billion in...